This article is more than 5 years old. Information may no longer be current.

Notice of allowance for patent on corneal wound treatment issued to RegeneRx

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RegeneRx Biopharmaceuticals has been issued a notice of allowance by the U.S. Patent and Trademark Office for a new patent for treating corneal wounds using thymosin beta 4 or related therapeutic peptides, according to a press release.

Thymosin beta 4 (Tβ4) is the active ingredient in the company’s drug candidate, RGN-259, a preservative-free eye drop for patients with corneal wounds.

RGN-259 is currently in phase 3 clinical trials in the United States, where RegeneRx has licensed its rights to ReGenTree LLC.

“We believe this patent will complement our recently issued dry eye patent by expanding our intellectual property portfolio in the ophthalmic field and benefit our ReGenTree [joint venture] as it continues to develop products to treat various eye injuries and disorders,” J.J. Finkelstein, president and CEO of RegeneRx, said in the release.